Seattle Genetics, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (25)

Latest Posts

About This Stock More About This Stock
Healthcare Investing Ideas Big And Small
Article By: Marc Lichtenfeld
Monday, January 15, 2018 9:00 PM EDT
With a dire need for growth, many in the industry expect the larger biotech and pharmaceutical companies to open their wallets and acquire smaller companies with novel drugs in development.
In this article: BMY, GSK, JNJ, PFE, AVXL, IMMP, BMRN, FOLD, SGEN, MBOT
Read
Seattle Genetics Upgraded To Overweight From Equal Weight At Barclays
Article By: The Fly
Friday, October 20, 2017 8:02 AM EDT
Barclays analyst Geoff Meacham upgraded Seattle Genetics to Overweight and raised his price target for the shares to $70 from $60.
In this article: SGEN Also: REGN
Read
5 Drug Stocks Well Poised To Beat Q2 Earnings Estimates
Article By: Zacks Investment Research
Thursday, July 13, 2017 4:58 PM EDT
The pharma/biotech sector has picked up this year after being battered by the drug pricing controversy in 2016. The first half has been pretty strong for companies in the space.
In this article: MRK, SGEN, VNDA, CELG, GILD
Read
Seattle Genetics Eliminates $2 Billion Deal With Immunomedics
Article By: Terry Chrisomalis
Saturday, May 6, 2017 1:39 PM EDT
On Friday, it was announced that Seattle Genetics had ended a potential $2 billion deal with Immunomedics. The initial deal was proposed back in February of this year.
In this article: SGEN, IMMU
Read
2017 Biotech Breakout Coming
Article By: Rod Raynovich
Monday, May 1, 2017 8:56 PM EDT
We expect a biotech breakout to 52 week highs in the coming months because of new products, good clinical news and M&A. Biotech has survived several tweet storms from Trump and many negative articles on drug pricing.
In this article: BMY, BMRN, IBB, INCY, REGN, SGEN, GILD, VRTX, XBI, ABBV, QQQ
Read

PARTNER HEADLINES

Latest Tweets for $SGEN

No tweets yet!

$SGEN

Large Cap Biopharmaceuticals Performance Update 2018: Part 2
Harry Goldstein 2/20/2018 9:31:10 PM

Why did you decide to purchase $SGEN?

Seattle Genetics Receives FDA Halt On Several Phase 1 Studies
Caitlin Snow 1/3/2017 7:11:44 PM

A real tragedy, not just for $SGEN investors, but for the families of those who died as a result of the trials. How likely is it that the company can bounce back from something like this?

1 to 2 of 2 comments